Maximilian F. Blank

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

Journal: Blood advances
Published: February 25, 2026

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

Journal: Blood advances
Published: February 25, 2026

Functional characterization of snoRNA-derived RNA (sdRNA) expression in healthy hematopoiesis and acute myeloid leukemia.

Functional characterization of snoRNA-derived RNA (sdRNA) expression in healthy hematopoiesis and acute myeloid leukemia.

Journal: Leukemia
Published: December 22, 2025

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.

Journal: Blood
Published: December 08, 2024

The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance.

The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance.

Journal: Leukemia
Published: December 06, 2023

The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia.

The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia.

Journal: International journal of cancer
Published: May 25, 2023

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations.

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations.

Journal: Leukemia
Published: May 05, 2023

The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia.

The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia.

Journal: Leukemia
Published: November 05, 2022

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.

Journal: Leukemia
Published: May 23, 2022

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.

Journal: Blood
Published: September 27, 2021

CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.

CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.

Journal: International journal of cancer
Published: March 01, 2021

The seven faces of SIRT7.

The seven faces of SIRT7.

Journal: Transcription
Published: January 10, 2017
Showing 1-12 of 14

Last Updated: 09/26/2026